Los puntos clave no están disponibles para este artículo en este momento.
Neuroendocrine bladder cancer (NEBC) poses a formidable clinical challenge and attracts keen interests to explore immunotherapy as a viable treatment option. However, a comprehensive immunogenomic landscape has yet to be thoroughly investigated.
Zang et al. (Tue,) studied this question.